Molecular Imaging

Molecular imaging (also called nuclear medicine or nuclear imaging) can image the function of cells inside the body at the molecular level. This includes the imaging modalities of positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. How does PET and SPECT imaging work? Small amounts of radioactive material (radiopharmaceuticals) injected into a patient. These can use sugars or chemical traits to bond to specific cells. The radioactive material is taken up by cells that consume the sugars. The radiation emitted from inside the body is detected by photon detectors outside the body. Computers take the data to assemble images of the radiation emissions. Nuclear images may appear fuzzy or ghostly rather than the sharper resolution from MRI and CT.  But, it provides metabolic information at a cellular level, showing if there are defects in the function of the heart, areas of very high metabolic activity associated with cancer cells, or areas of inflammation, data not available from other modalities. These noninvasive imaging exams are used to diagnose cancer, heart disease, Alzheimer’s and Parkinson’s disease, bone disorders and other disorders. 

Thumbnail

GE Healthcare sells radiopharmacy network to now-largest molecular imaging firm in the U.S.

Radioisotope Life Sciences currently operates 31 pharmacies across 18 states.

Thumbnail

Despite higher Alzheimer’s risk, patients can handle amyloid PET exam results

Those who learned they had elevated amyloid levels did not suffer from more short-term anxiety, depression or suicical thoughts, experts reported in JAMA Neurology.

Thumbnail

Biopharmaceutical firm AC Immune wins funding for ‘game-changing’ Parkinson’s PET agent

The win comes shortly after the Swiss-based company shared positive early results for its radiotracer during the Alzheimer’s Association International Conference.

Thumbnail

Lifelong thinking skills create ‘cognitive reserve’ protection against Alzheimer’s-related brain changes

Normal scores on thinking and memory tests at the start of a 14-year-long study were associated with fewer problems later in life, regardless of amyloid brain plaques.

Thumbnail

First patients receive new PET tracer; Canadian orgs sign isotope deal, and more molecular imaging updates

Blue Earth Diagnostics announced that it has administered its new radiohybrid imaging agent to patients taking part in a clinical trial for prostate cancer.

Molecular imaging pioneer, beloved radiologist passes away

In addition to his dedication to early cancer detection, the renowned 57-year-old physician developed a number of FDG PET algorithms used for managing cancer patients.

Doctors at odds over low-dose radiation treatment in COVID-19 patients

At least a dozen trials across the globe are underway testing LDRT as a treatment for virus-related pneumonia, but some experts aren't convinced.

Thumbnail

Most countries face nuclear imaging supply issues, and COVID-19 has only exacerbated the problem

A team of international researchers queried 35 countries representing nearly 75% of all global nuclear medicine sites, publishing their findings in the Journal of Nuclear Medicine.